Celadon Pharmaceuticals (LON:CEL) Trading Down 29.3% – Here’s Why

Celadon Pharmaceuticals Plc (LON:CELGet Free Report) fell 29.3% during trading on Tuesday . The stock traded as low as GBX 14 ($0.18) and last traded at GBX 19.80 ($0.25). 368,578 shares were traded during mid-day trading, an increase of 370% from the average session volume of 78,498 shares. The stock had previously closed at GBX 28 ($0.35).

Celadon Pharmaceuticals Stock Down 7.1 %

The company has a current ratio of 1.92, a quick ratio of 6.97 and a debt-to-equity ratio of 194.82. The firm has a market capitalization of £12.67 million, a P/E ratio of -235.00 and a beta of -0.26. The company’s fifty day simple moving average is GBX 30.85 and its 200 day simple moving average is GBX 55.11.

Celadon Pharmaceuticals Company Profile

(Get Free Report)

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

Featured Stories

Receive News & Ratings for Celadon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celadon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.